FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial.

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...

Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Daiichi Sankyo (OTCPK:DSKYF ... Agency (EMA), endorsed its antibody-drug conjugate Dato-DXd marketed with AstraZeneca (NASDAQ:AZN) as a late-line option for certain cases of breast cancer.